PROPANC BIOPHARMA, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $624.6K | $-3.1M | $2.3K |
| FY2022 | $926.4K | $-3.0M | $4.1K |
| FY2023 | $390.5K | $-3.1M | — |
| FY2024 | $399.3K | $-3.8M | — |
| FY2025 | $537.9K | $13.9M | — |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $624.6K | $-3.1M | $2.3K |
| FY2022 | $926.4K | $-3.0M | $4.1K |
| FY2023 | $390.5K | $-3.1M | — |
| FY2024 | $399.3K | $-3.8M | — |
| FY2025 | $537.9K | $13.9M | — |